MICROBIX BIOSYSTEMS INC (MBX.CA) Stock Fundamental Analysis
TSX:MBX - Toronto Stock Exchange - CA59501P1045 - Common Stock - Currency: CAD
Overall MBX gets a fundamental rating of 7 out of 10. We evaluated MBX against 25 industry peers in the Biotechnology industry. MBX has outstanding health and profitabily ratings, belonging to the best of the industry. This is a solid base for any company. MBX has both an excellent growth and valuation score. This means it is growing and it is still cheap. This is a rare combination! This makes MBX very considerable for value and growth and quality investing!
1. Profitability
1.1 Basic Checks
MBX had positive earnings in the past year.
In the past year MBX had a positive cash flow from operations.
The reported net income has been mixed in the past 5 years: MBX reported negative net income in multiple years.
MBX had a positive operating cash flow in 4 of the past 5 years.
1.2 Ratios
MBX has a better Return On Assets (3.97%) than 92.00% of its industry peers.
The Return On Equity of MBX (5.04%) is better than 96.00% of its industry peers.
With an excellent Return On Invested Capital value of 4.29%, MBX belongs to the best of the industry, outperforming 92.00% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 3.97% | ||
| ROE | 5.04% | ||
| ROIC | 4.29% |
ROA(3y)4.84%
ROA(5y)-2.84%
ROE(3y)6.48%
ROE(5y)-11.45%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
With an excellent Profit Margin value of 6.89%, MBX belongs to the best of the industry, outperforming 92.00% of the companies in the same industry.
MBX's Profit Margin has improved in the last couple of years.
Looking at the Operating Margin, with a value of 9.61%, MBX belongs to the top of the industry, outperforming 92.00% of the companies in the same industry.
MBX's Operating Margin has improved in the last couple of years.
The Gross Margin of MBX (57.74%) is better than 88.00% of its industry peers.
MBX's Gross Margin has improved in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 9.61% | ||
| PM (TTM) | 6.89% | ||
| GM | 57.74% |
OM growth 3Y-14.86%
OM growth 5Y15.81%
PM growth 3Y-7.25%
PM growth 5Y128.26%
GM growth 3Y0.68%
GM growth 5Y4.41%
2. Health
2.1 Basic Checks
MBX has a Return on Invested Capital (ROIC), which is below the Cost of Capital (WACC), which means it is destroying value.
MBX has less shares outstanding than it did 1 year ago.
The number of shares outstanding for MBX has been increased compared to 5 years ago.
MBX has a better debt/assets ratio than last year.
2.2 Solvency
MBX has an Altman-Z score of 3.36. This indicates that MBX is financially healthy and has little risk of bankruptcy at the moment.
Looking at the Altman-Z score, with a value of 3.36, MBX belongs to the top of the industry, outperforming 92.00% of the companies in the same industry.
MBX has a debt to FCF ratio of 2.38. This is a good value and a sign of high solvency as MBX would need 2.38 years to pay back of all of its debts.
MBX has a Debt to FCF ratio of 2.38. This is amongst the best in the industry. MBX outperforms 88.00% of its industry peers.
MBX has a Debt/Equity ratio of 0.17. This is a healthy value indicating a solid balance between debt and equity.
With a decent Debt to Equity ratio value of 0.17, MBX is doing good in the industry, outperforming 64.00% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.17 | ||
| Debt/FCF | 2.38 | ||
| Altman-Z | 3.36 |
ROIC/WACC0.59
WACC7.29%
2.3 Liquidity
MBX has a Current Ratio of 9.36. This indicates that MBX is financially healthy and has no problem in meeting its short term obligations.
MBX has a better Current ratio (9.36) than 88.00% of its industry peers.
MBX has a Quick Ratio of 6.37. This indicates that MBX is financially healthy and has no problem in meeting its short term obligations.
With an excellent Quick ratio value of 6.37, MBX belongs to the best of the industry, outperforming 88.00% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 9.36 | ||
| Quick Ratio | 6.37 |
3. Growth
3.1 Past
MBX shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -44.66%.
The Earnings Per Share has been growing by 8.58% on average over the past years. This is quite good.
Looking at the last year, MBX shows a decrease in Revenue. The Revenue has decreased by -4.65% in the last year.
Measured over the past years, MBX shows a quite strong growth in Revenue. The Revenue has been growing by 13.62% on average per year.
EPS 1Y (TTM)-44.66%
EPS 3Y8.58%
EPS 5YN/A
EPS Q2Q%-96.3%
Revenue 1Y (TTM)-4.65%
Revenue growth 3Y10.96%
Revenue growth 5Y13.62%
Sales Q2Q%-5.47%
3.2 Future
MBX is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 51.83% yearly.
Based on estimates for the next years, MBX will show a very strong growth in Revenue. The Revenue will grow by 21.86% on average per year.
EPS Next Y50%
EPS Next 2Y41.42%
EPS Next 3Y51.83%
EPS Next 5YN/A
Revenue Next Year7.14%
Revenue Next 2Y20.68%
Revenue Next 3Y21.86%
Revenue Next 5YN/A
3.3 Evolution
The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
4. Valuation
4.1 Price/Earnings Ratio
Based on the Price/Earnings ratio of 30.00, the valuation of MBX can be described as expensive.
92.00% of the companies in the same industry are more expensive than MBX, based on the Price/Earnings ratio.
When comparing the Price/Earnings ratio of MBX to the average of the S&P500 Index (26.92), we can say MBX is valued inline with the index average.
A Price/Forward Earnings ratio of 7.43 indicates a rather cheap valuation of MBX.
Based on the Price/Forward Earnings ratio, MBX is valued cheaper than 100.00% of the companies in the same industry.
MBX's Price/Forward Earnings ratio indicates a rather cheap valuation when compared to the S&P500 average which is at 21.46.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 30 | ||
| Fwd PE | 7.43 |
4.2 Price Multiples
MBX's Enterprise Value to EBITDA ratio is rather cheap when compared to the industry. MBX is cheaper than 100.00% of the companies in the same industry.
Based on the Price/Free Cash Flow ratio, MBX is valued cheaply inside the industry as 92.00% of the companies are valued more expensively.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 18.79 | ||
| EV/EBITDA | 8.54 |
4.3 Compensation for Growth
MBX's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
MBX has an outstanding profitability rating, which may justify a higher PE ratio.
MBX's earnings are expected to grow with 51.83% in the coming years. This may justify a more expensive valuation.
PEG (NY)0.6
PEG (5Y)N/A
EPS Next 2Y41.42%
EPS Next 3Y51.83%
5. Dividend
5.1 Amount
MBX does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
TSX:MBX (6/23/2025, 7:00:00 PM)
0.3
0 (0%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners0.43%
Inst Owner ChangeN/A
Ins Owners14.97%
Ins Owner ChangeN/A
Market Cap42.24M
Analysts80
Price Target0.92 (206.67%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 30 | ||
| Fwd PE | 7.43 | ||
| P/S | 1.86 | ||
| P/FCF | 18.79 | ||
| P/OCF | 10.75 | ||
| P/B | 1.36 | ||
| P/tB | 1.56 | ||
| EV/EBITDA | 8.54 |
EPS(TTM)0.01
EY3.33%
EPS(NY)0.04
Fwd EY13.47%
FCF(TTM)0.02
FCFY5.32%
OCF(TTM)0.03
OCFY9.3%
SpS0.16
BVpS0.22
TBVpS0.19
PEG (NY)0.6
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 3.97% | ||
| ROE | 5.04% | ||
| ROCE | 5.96% | ||
| ROIC | 4.29% | ||
| ROICexc | 7.12% | ||
| ROICexgc | 8.69% | ||
| OM | 9.61% | ||
| PM (TTM) | 6.89% | ||
| GM | 57.74% | ||
| FCFM | 9.9% |
ROA(3y)4.84%
ROA(5y)-2.84%
ROE(3y)6.48%
ROE(5y)-11.45%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3Y-16.73%
ROICexcg growth 5Y20.32%
ROICexc growth 3Y-19.11%
ROICexc growth 5Y24.01%
OM growth 3Y-14.86%
OM growth 5Y15.81%
PM growth 3Y-7.25%
PM growth 5Y128.26%
GM growth 3Y0.68%
GM growth 5Y4.41%
F-Score6
Asset Turnover0.58
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.17 | ||
| Debt/FCF | 2.38 | ||
| Debt/EBITDA | 1.36 | ||
| Cap/Depr | 99.49% | ||
| Cap/Sales | 7.4% | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 101.47% | ||
| Profit Quality | 143.69% | ||
| Current Ratio | 9.36 | ||
| Quick Ratio | 6.37 | ||
| Altman-Z | 3.36 |
F-Score6
WACC7.29%
ROIC/WACC0.59
Cap/Depr(3y)133.78%
Cap/Depr(5y)133.99%
Cap/Sales(3y)8.11%
Cap/Sales(5y)7.74%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-44.66%
EPS 3Y8.58%
EPS 5YN/A
EPS Q2Q%-96.3%
EPS Next Y50%
EPS Next 2Y41.42%
EPS Next 3Y51.83%
EPS Next 5YN/A
Revenue 1Y (TTM)-4.65%
Revenue growth 3Y10.96%
Revenue growth 5Y13.62%
Sales Q2Q%-5.47%
Revenue Next Year7.14%
Revenue Next 2Y20.68%
Revenue Next 3Y21.86%
Revenue Next 5YN/A
EBIT growth 1Y59.46%
EBIT growth 3Y-5.54%
EBIT growth 5Y31.58%
EBIT Next Year-29.47%
EBIT Next 3Y21.52%
EBIT Next 5YN/A
FCF growth 1Y310.13%
FCF growth 3Y41.04%
FCF growth 5YN/A
OCF growth 1Y260.45%
OCF growth 3Y27.25%
OCF growth 5Y155.41%